SYDNEY, Australia and MINNEAPOLIS, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is pleased to release an updated company presentation, which is attached to this announcement. The presentation will be used for a series of meetings in the coming weeks.
About Medibio Limited
Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au
| Further Information: | Website: www.medibio.com.au |
| Medibio Enquiries: | Australian Media Enquiries: |
| Josh Purdy | Peter Taylor |
| Senior Public Relations Manager | NWR Communications |
| Medibio Limited | peter@nwrcommunications.com.au |
| josh.purdy@medibio.com.au | T: +61 (0) 412 036 231 |
| T: +1 952 314 1216 |
